Iron Deficiency (Without Anemia)
Conditions
Brief summary
The aim of this study is to investigate the hepcidin hormone response after intravenous iron administration.
Detailed description
Intravenous iron is often administered when peroral iron is insufficient to correct iron-deficiency or not tolerated. Few studies have shown a relationship between pretherapeutic serum hepcidin levels and response to intravenous iron infusion: the lower the pre-infusion hepcidin level, the fewer red blood cell concentrates were used to correct anaemia. However, there are no studies investigating hepcidin levels after intravenous iron supplementation. Furthermore, some studies showed an increase in hepcidin 24 hours after ingesting oral iron supplements, impairing the iron uptake the next day. However, how long hepcidin is increased after intravenous iron administration is unknown. Prolonged serum hepcidin concentrations after an iron infusion would reduce intestinal iron absorption and continued, simultaneous oral iron therapy would be pointless. This study investigates whether and how serum hepcidin concentrations change after intravenous iron therapy. Women with iron deficiency (serum ferritin below 30ng/ml) without anaemia (hemoglobin \>117g/l) receive 500mg iron (Ferinject®) intravenously. Serum hepcidin levels are measured before therapy (day 0) 2 days (day 2) and 7 days (day 7) after infusion.
Interventions
None listed
Sponsors
Pierre-Alexandre Krayenbühl
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* informed consent as documented by signature * iron-deficiency (serum ferritin \<30ng/ml) * female gender * premenopausal * age \>18 years * body mass index (BMI) in normal range (18-25 kg/m²) * the participant is linguistically and cognitively able to understand the study procedure
Exclusion criteria
* anaemia (hemoglobin \<117g/l) * allergy or contraindications for iron infusions * anamnestic current pregnancy * breastfeeding * chronic inflammatory diseases (e.g. colitis) * liver disease (alanine transaminase (ALT) \>35 U/l) * increased C-reactive protein (CRP) (\>5mg/l) * intake of dietary supplements containing iron (last 7 days)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Hepcidin Change | 1 week | The change of serum hepcidin levels over time (days 0, 2, 7) after intravenous iron administration. |
Outcome results
None listed